<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00870155</url>
  </required_header>
  <id_info>
    <org_study_id>12789</org_study_id>
    <secondary_id>I3E-BM-MSAC</secondary_id>
    <secondary_id>2007-001480-30</secondary_id>
    <secondary_id>MBP8298-SP-02</secondary_id>
    <nct_id>NCT00870155</nct_id>
  </id_info>
  <brief_title>A Study for Patients With Multiple Sclerosis</brief_title>
  <acronym>MAESTRO-02</acronym>
  <official_title>An Open Label Follow-On Study to Assess the Ongoing Safety of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioMS Technology Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To obtain additional safety data in subjects who have previously completed the MBP8298-01
      study &quot;A Double Blind Placebo Controlled Multi-Centre to Evaluate the Efficacy and Safety of
      MBP8298 in Subjects with Secondary Multiple Sclerosis&quot; Dirucotide is generic name for
      MBP8298.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Negative efficacy results of the MAESTRO-01 trial
  </why_stopped>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess clinically significant effects of MBP8298 synthetic peptide in all subjects by collecting adverse event, ECG, laboratory, and physical exam outcomes</measure>
    <time_frame>every 6 mos</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree of change in Kurtzke Expended Disability Status (EDSS)</measure>
    <time_frame>every 6mos</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain atrophy by MRI</measure>
    <time_frame>every 6mos</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity analysis of T2 and Gadolinium enhancing lesions</measure>
    <time_frame>every 6mos</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion burden</measure>
    <time_frame>every 6mos</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of change in MS Functional Composite Index (MSFC)</measure>
    <time_frame>every 6mos</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rates</measure>
    <time_frame>every 6mos</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by Short Form 36 (SF-36) or MSQoL54</measure>
    <time_frame>every 6mos</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">546</enrollment>
  <condition>Secondary Progressive Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Dirucotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dirucotide</intervention_name>
    <description>500mg, intravenous, every 6mos until regulatory approval, denial or sponsor termination</description>
    <arm_group_label>Dirucotide</arm_group_label>
    <other_name>MBP8298</other_name>
    <other_name>LY2820671</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects participating in this study must have completed treatment and all required
             evaluations in the previous MBP8298-01 study &quot;A Double Blind Placebo Controlled
             Multi-Centre Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects with
             Secondary Progressive Multiple Sclerosis&quot;,

          2. Subject must be able and willing to give meaningful, written informed consent prior to
             participation in the trial in accordance with regulatory requirements,

          3. In the Investigator's opinion, subjects must be reliable, compliant and agree to
             cooperate with all trial evaluations.

        Exclusion Criteria:

          1. Use of any concomitant disease modifying therapy for Multiple Sclerosis e.g.
             ÃŸ-interferon, glatiramer acetate or mitoxantrone, cyclophosphamide, methotrexate,
             azathioprine, or any other immuno-modulating (e.g. IVIG) or immunosuppressive drugs
             including recombinant or non-recombinant cytokines.

          2. Any medical, psychiatric or other condition that could result in a subject not being
             able to give fully informed consent, or to comply with the protocol requirements.

          3. Any other condition that, in the Investigator's opinion, makes the subject unsuitable
             for participation in the study.

          4. Females who are breast feeding, pregnant or not using a medically approved method of
             contraception regularly.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9am-5pm Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Michaels Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Copenhagen University Hospital</name>
      <address>
        <city>Kobenhavn</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Terveystalo Turku Kuvantaminen</name>
      <address>
        <city>Turku</city>
        <zip>20101</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heinrich Heine Universitaets</name>
      <address>
        <city>Duesseldorf</city>
        <state>North Rhine Westphalia</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vecmilgravis Hospital</name>
      <address>
        <city>Riga</city>
        <zip>1015</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maaslandziekenhuis</name>
      <address>
        <city>Sittard</city>
        <zip>6131BK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Duran I Reynals</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhus</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walton Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L97LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Latvia</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2009</study_first_submitted>
  <study_first_submitted_qc>March 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2009</study_first_posted>
  <disposition_first_submitted>September 7, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>September 7, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 9, 2010</disposition_first_posted>
  <last_update_submitted>September 7, 2010</last_update_submitted>
  <last_update_submitted_qc>September 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

